What is the 13F Pro Quality Score for KRRO?

13F Pro ranks Korro Bio, Inc. (KRRO) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View KRRO's current score at https://13fpro.ai/research/KRRO (free sign-up required for the full ranking).

Where does 13F Pro source KRRO data?

All Korro Bio, Inc. fundamentals and ownership data come directly from SEC EDGAR. Korro Bio, Inc. files with the SEC under CIK 1703647. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is KRRO in?

Korro Bio, Inc. (KRRO) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is KRRO research updated on 13F Pro?

KRRO's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Korro Bio, Inc.(KRRO)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1703647 KRRO stock profile & AI dashboard →

13F Pro Quality Score

5.8/100

Rank #2,845 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

3.1/100

Profitability

1.8/100

Balance Sheet

1.4/100

Earnings Quality

30.0/100

Free Cash Flow

1.7/100

Institutional Flow

46.9/100

Revenue Scale

2.3/100

Dilution Risk

2.7/100

KRRO Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Korro Bio, Inc. (KRRO), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores KRRO at 5.8/100 on a 32-signal composite quality model, placing it at rank #2,845 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include balance sheet strength (1.4) and free cash flow (1.7), which score below median versus the broader universe. Shareholder dilution risk is elevated at 2.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Korro Bio, Inc. reports net income of $-19.6M, free cash flow of $-16.1M. Top institutional holders of KRRO by reported 13-F value include Lynx1 Capital Management, NEA Management Company,, Atlas Venture Life Science Advisors,, based on the most recent SEC filings. KRRO trades on the Nasdaq exchange and files with the SEC under CIK 1703647. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate KRRO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Korro Bio, Inc. directly from SEC EDGAR. Korro Bio, Inc.'s 13F Pro composite quality score has ranged between 5 and 26 since 2025, currently 5.8 — a declining long-term trajectory across 12 quarterly and live scoring snapshots.

Revenue

Q1 2026

$0.00

Net Income

Q1 2026

$-19.6M

Free Cash Flow

Q1 2026

$-16.1M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-100.0% YoY

$0.00FY 2022

FY18 —FY20 $37.0MFY21 $14.1MFY22 $0.00

Net Income

+31.5% YoY

$-58.0MFY 2022

FY18 $-19.2MFY20 $-26.5MFY21 $-84.7MFY22 $-58.0M

Operating Income

+29.8% YoY

$-59.0MFY 2022

FY18 $-18.9MFY20 $-27.6MFY21 $-84.0MFY22 $-59.0M

EPS (Diluted)

$-227.42FY 2022

FY18 —FY20 —FY21 —FY22 $-227.42

Total Assets

-34.6% YoY

$121.2MFY 2022

FY18 $44.5MFY20 $264.7MFY21 $185.4MFY22 $121.2M

Total Debt

+1100.5% YoY

$10.0MFY 2022

FY18 $349.0KFY20 —FY21 $833.0KFY22 $10.0M

Op. Cash Flow

+29.5% YoY

$-53.6MFY 2022

FY18 $-17.0MFY20 $-45.2MFY21 $-76.1MFY22 $-53.6M

Metric	FY 2022	FY 2021	FY 2020	FY 2018	FY 2017	FY 2016
Revenue	$0.00 -100.0%	$14.1M -62.0%	$37.0M	—	—	—
Net Income	$-58.0M +31.5%	$-84.7M -219.4%	$-26.5M -38.3%	$-19.2M +5.3%	$-20.2M	—
Operating Income	$-59.0M +29.8%	$-84.0M -205.0%	$-27.6M -45.4%	$-18.9M -16.2%	$-16.3M	—
EPS (Diluted)	$-227.42	—	—	—	—	—
Total Assets	$121.2M -34.6%	$185.4M -30.0%	$264.7M +494.2%	$44.5M	—	—
Total Debt	$10.0M +1100.5%	$833.0K	—	$349.0K	—	—
Operating Cash Flow	$-53.6M +29.5%	$-76.1M -68.3%	$-45.2M -165.4%	$-17.0M -16.5%	$-14.6M	—

AI Insight: KRRO Financial Trends

Q4 2025 net loss spiked to $50M — more than double the prior run-rate — before snapping back to $20M in Q1 2026, signaling a one-time charge rather than structural deterioration.

• Net loss surged to $50M in Q4 2025 versus a $18M–$26M quarterly range across all prior periods, suggesting a large non-recurring item.

• Revenue appeared in Q1 2025 at $3M but faded to $1M through Q3 2025 and $0M in Q1 2026, indicating no durable revenue stream yet.

• Operating cash outflow improved from $-24M in Q1 2025 to a steadier $-16M to $-19M range across Q2 2025–Q1 2026.

⚠ Q4 2025 operating loss of $50M needs explanation — if not one-time, it signals accelerating cash burn ahead.

⚠ Revenue has effectively returned to zero in Q1 2026; any partnership or milestone payments will be critical to monitor.

⚠ Debt and equity data are absent across all periods — balance sheet health and cash runway remain unverifiable from this data.

AI Insight: KRRO Ratio Trends

Data is nearly entirely absent — only ROA is available, and it shows a deepening cash-burn trajectory for this pre-revenue biotech.

• ROA deteriorated sharply from -34.5% in Q3 2024 to -61.8% on a TTM basis through Q1 2026, signaling accelerating asset consumption.

• ROA briefly stabilized around -34.5% to -37.5% across Q3 2024–Q4 2024 before resuming its decline in 2025.

⚠ TTM ROA of -61.8% is the worst reading in the dataset — monitor whether Q2 2026 shows any moderation in cash burn.

⚠ OpMargin, NPM, ROE, ROIC, and D/E are all unavailable — too little data to assess leverage or capital efficiency.

Get alerted when KRRO's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Korro Bio, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of KRRO

Lynx1 Capital Management LP
$17.4M1,538,296 sh
NEA Management Company, LLC
$14.7M1,297,893 sh
Atlas Venture Life Science Advisors, LLC
$12.9M1,137,149 sh
BALYASNY ASSET MANAGEMENT L.P.
$11.8M1,040,054 sh
VR Adviser, LLC
$11.4M1,009,500 sh
Affinity Asset Advisors, LLC
$8.0M706,904 sh
Nantahala Capital Management, LLC
$7.5M660,036 sh
ADAR1 Capital Management, LLC
$6.1M540,054 sh
BlackRock, Inc.
$5.2M460,006 sh
DRIEHAUS CAPITAL MANAGEMENT LLC
$5.1M450,045 sh

Fund	Value	Shares
Lynx1 Capital Management LP	$17.4M	1,538,296
NEA Management Company, LLC	$14.7M	1,297,893
Atlas Venture Life Science Advisors, LLC	$12.9M	1,137,149
BALYASNY ASSET MANAGEMENT L.P.	$11.8M	1,040,054
VR Adviser, LLC	$11.4M	1,009,500
Affinity Asset Advisors, LLC	$8.0M	706,904
Nantahala Capital Management, LLC	$7.5M	660,036
ADAR1 Capital Management, LLC	$6.1M	540,054
BlackRock, Inc.	$5.2M	460,006
DRIEHAUS CAPITAL MANAGEMENT LLC	$5.1M	450,045

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put KRRO on your watchlist

Track score changes the day Korro Bio, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is KRRO a good stock to buy?

13F Pro's AI-powered analysis of Korro Bio, Inc. (KRRO) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for KRRO are available on the KRRO stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own KRRO?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling KRRO. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Korro Bio, Inc.'s investment landscape.